| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |